Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.
Vilde D. Haakensen, MD, PhD
Advertisement
Articles by Vilde D. Haakensen, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas
2
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
3
Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026
4
Emiltatug Ledadotin Elicits Responses in Aggressive Adenoid Cystic Carcinoma
5